Why Clinical Trial Recruitment in Australia Is Slow: The Catchment Math
Australian sites are excellent. The bottleneck is not the site — it is how many eligible people live within reach of it.
September 4, 2026
7
min read
By
Julio G. Martinez-Clark, CEO, bioaccess®
Australia
Latin America
First-in-Human
Patient Recruitment
Medical Devices
Panama
What does Australia do well?
Concede this first, because it is true and because getting it wrong would cost you a good option. Australia has excellent investigators, world-class sites, and high data quality. Ethics review is professional, documentation is meticulous, and datasets from Australian early-phase sites hold up under regulatory scrutiny. If you are choosing on rigor alone, Australia is a defensible answer.
This post is not about rigor. It is about fit for purpose on one specific variable: how many eligible candidates a site can actually reach. That variable is decided by geography and demographics, not by investigator skill, and it is the variable that most often determines whether a first-in-human cohort closes this year or next.
How big is the Australian candidate pool really?
Start with the top of the funnel. Australia's five largest metros total about 17.9M people:
| Metro | Population |
|---|---|
| Sydney | 5.6M |
| Melbourne | 5.4M |
| Brisbane | 2.8M |
| Perth | 2.5M |
| Adelaide | 1.5M |
| Five-metro total | ~17.9M |
| Metro Sao Paulo (single metro) | ~23M |
| Mexico City | ~23M |
| Buenos Aires | ~16.7M |
| Bogota | ~12.8M (more than double Sydney) |
Read that table twice. Australia's entire five-metro catchment is fewer people than metro Sao Paulo alone. Mexico City matches Sao Paulo at roughly 23M. Buenos Aires at about 16.7M nearly equals all five Australian metros combined. Bogota at about 12.8M is more than double Sydney, Australia's largest city. And a first-in-human study does not recruit from five metros at once — it recruits from one or two sites.
Figures above follow ABS 2025 population estimates for Australian metros and Statista metro population data for Latin America. No other numbers are used in this analysis.
Why does population density decide enrollment speed?
Absolute population is only half the story. The other half is how tightly those people are packed around your clinic.
| Country | Population density (people per km²) |
|---|---|
| Australia | ~3 (among the lowest on earth) |
| Brazil | ~25 |
| Colombia | ~46 |
| Panama | ~60 |
| Dominican Republic | ~230 |
| El Salvador | ~300+ (roughly 90x Australia) |
Density is the multiplier that converts a map into an enrollment curve. Early device studies require repeat in-person visits: screening, the index procedure, and a follow-up schedule that can run months. Every additional kilometer between a patient's home and the site raises the odds of a screen-fail-by-logistics, a missed visit, or a withdrawal.
What is the actual mechanism behind slow recruitment?
Be precise here, because the lazy version of this argument is wrong. Australia is roughly 86% urbanized. It is not short of big cities and it is not a rural country. The mechanism is different:
- Australian metros are comparatively low-density sprawl; Latin American metros are dense.
- Within the same drive-time radius of a clinic, a Latin American site can reach many times more eligible candidates.
- The relevant number is never the metro's population on paper — it is the reachable, retainable pool inside a workable travel radius for repeat follow-up.
- A denser catchment also tightens the screening funnel: more candidates screened per week means the eligible subset appears sooner.
That is the whole claim, and it is a geometry claim rather than a quality claim. A brilliant investigator with a small reachable pool still enrolls slowly. The same protocol in a dense Panama catchment reaches its cohort faster for reasons that have nothing to do with who is better at their job.
Is Australia's early-phase site market saturated?
Comparatively, yes. Australia's early-phase site market is well established and heavily used, which means the small number of high-capability early-phase units are competing for the same limited candidate pool across many concurrent studies. Popularity is a consequence of quality — but it also means your protocol is queuing behind other sponsors for the same patients.
This is why fast approval does not rescue a slow enrollment curve. Approval speed and enrollment speed are separate products, a point we work through in TGA CTN versus Latin America on first-patient-in timelines. Sponsors who discovered the gap the hard way are the subject of the three years lost in Australia before moving first-in-human to Latin America.
How should sponsors design around this?
Model catchment before you pick a country. Ask each candidate site for the eligible population inside a realistic drive-time radius, not the metro headline, and ask how many competing protocols are recruiting from the same pool. If the reachable pool cannot support your cohort inside your milestone window, no amount of regulatory speed fixes it.
For the full head-to-head across cost, catchment, diversity, travel, and entity requirements, start with the pillar: Australia vs. Latin America for first-in-human medical device trials. For the broader option set, see alternatives to Australia for first-in-human trials in 2026 and how we run studies in our first-in-human CRO practice.
Frequently asked questions
What is the fastest next step?
Send us your indication, your inclusion criteria, and your cohort size, and we will tell you which catchments can realistically deliver it and how fast — including the cases where an Australian site is the better fit. Get a first-in-human feasibility read in 72 hours.
Get your feasibility read
See how we run first-in-human